ONCOLOGY / CLINICAL RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The systemic immune-inflammation index (SII), based on peripheral lymphocyte, neutrophil, and platelet counts, has recently been investigated as a prognostic marker in several tumors. However, the SII has rarely been reported in skin cancers. In this study, we aimed to assess the association between SII values and the risk of occurrence of skin cancers.

Material and methods:
This cross-sectional study was based on National Health and Nutrition Examination Survey data from 2010 to 2018 and involved 32,012 participants. The SII was calculated as the platelet count × neutrophil count/lymphocyte count. A weighted multivariate logistic analysis was conducted to examine the relationship between SII values and the occurrence of skin cancers. In addition, a subgroup analysis and a sensitivity analysis were conducted to identify underlying moderators and the stability of the relationship, respectively.

Results:
Compared with participants in the lowest quartile of SII values, the odds ratios for non-melanoma skin cancer were 1.650 (95% CI: 1.158–2.352) for participants in the quartile with the highest SII values after multivariate adjustments. In subgroup analyses, we found significant interactions between log-transformed SII values and age (p < 0.001 for interaction), race (p < 0.001 for interaction), education level (p < 0.001 for interaction), marital status (p < 0.001 for interaction), and annual household incomes (p < 0.001 for interaction) in the association with non-melanoma skin cancer.

Conclusions:
Our findings suggest a positive association between high SII values and skin cancers in the U.S. population. Age, levels of education, marital status, and annual household incomes affect the positive association between high SII values and non-melanoma skin cancers.

 
REFERENCES (35)
1.
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol 2015; 151: 1081-6.
 
2.
Perera E, Gnaneswaran N, Staines C, Win AK, Sinclair R. Incidence and prevalence of non-melanoma skin cancer in Australia: a systematic review. Australas J Dermatol 2015; 56: 258-67.
 
3.
Doré JF, Chignol MC. Tanning salons and skin cancer. Photochem Photobiol Sci 2012; 11: 30-7.
 
4.
Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol 2014; 810: 120-40.
 
5.
Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-35.
 
6.
Wang J, Zhou D, Dai Z, Li X. Association between systemic immune-inflammation index and diabetic depression. Clin Interv Aging 2021; 16: 97-105.
 
7.
Li J, Cao D, Huang Y, et al. The prognostic and clinicopathological significance of systemic immune-inflammation index in bladder cancer. Front Immunol 2022; 13: 865643.
 
8.
Yu L, Zheng S, Yang J, Fu Z, Zhu X, Su K. Association between the systemic immune inflammation index and recurrence or metastasis after interventional therapy in patients with primary liver cancer- a retrospective cohort study. J Gastrointest Oncol 2023; 14: 780-8.
 
9.
Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Labor Analysis 2019; 33: e22964.
 
10.
Jomrich G, Paireder M, Kristo I, et al. High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma. Ann Surg 2021; 273: 532-41.
 
11.
Huang H, Liu Q, Zhu L, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep 2019; 9: 3284.
 
12.
Susok L, Said S, Reinert D, et al. The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy. J Cancer Res Clin Oncol 2022; 148: 3103-8.
 
13.
Tang Y, Peng B, Liu J, Liu Z, Xia Y, Geng B. Systemic immune-inflammation index and bone mineral density in postmenopausal women: a cross-sectional study of the national health and nutrition examination survey (NHANES) 2007-2018. Front Immunol 2022; 13: 975400.
 
14.
Xu M, Chen R, Liu L, et al. Systemic immune-inflammation index and incident cardiovascular diseases among middle-aged and elderly Chinese adults: the Dongfeng-Tongji cohort study. Atherosclerosis 2021; 323: 20-9.
 
15.
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013; 13: 759-71.
 
16.
Suzuki K. Chronic inflammation as an immunological abnormality and effectiveness of exercise. Biomolecules 2019; 9: 223.
 
17.
Jomrich G, Gruber ES, Winkler D, et al. Systemic immune-inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection. J Gastrointest Surg 2020; 24: 610-8.
 
18.
Teng H, Zhang RS, Xie JH, Zhang HZ. Effect of systemic immunoinflammatory index on prognosis of patients with small cell lung cancer. J Hebei Med Univ 2021; 42: 886-90.
 
19.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44.
 
20.
Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer 2014; 110: 1409-12.
 
21.
Higgins S, Nazemi A, Chow M, Wysong A. Review of nonmelanoma skin cancer in African Americans, Hispanics, and Asians. Dermatol Surg 2018; 44: 903-10.
 
22.
Skidmore RA Jr, Flowers FP. Nonmelanoma skin cancer. Med Clin N Am 1998; 82: 1309-23.
 
23.
Fontanillas P, Alipanahi B, Furlotte NA, et al. Disease risk scores for skin cancers. Nat Commun 2021; 12: 160.
 
24.
Albert A, Knoll MA, Conti JA, Zbar RIS. Non-melanoma skin cancers in the older patient. Curr Oncol Rep 2019; 21: 79.
 
25.
Fahradyan A, Howell AC, Wolfswinkel EM, Tsuha M, Sheth P, Wong AK. Updates on the management of non-melanoma skin cancer (NMSC). Healthcare (Basel, Switzerland) 2017; 5: 82.
 
26.
Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet (London, England) 2010; 375: 673-85.
 
27.
Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H. Free radical-induced damage to DNA: mechanisms and measurement. Free Rad Biol Med 2002; 32: 1102-15.
 
28.
Fest J, Ruiter R, Ikram MA, Voortman T, van Eijck CHJ, Stricker BH. Reference values for white blood-cell-based inflammatory markers in the Rotterdam Study: a population-based prospective cohort study. Sci Rep 2018; 8: 10566.
 
29.
Gordon R. Skin cancer: an overview of epidemiology and risk factors. Semin Oncol Nursing 2013; 29: 160-9.
 
30.
Halder RM, Bridgeman-Shah S. Skin cancer in African Americans. Cancer 1995; 75: 667-73.
 
31.
Liu-Smith F, Jia J, Zheng Y. UV-induced molecular signaling differences in melanoma and non-melanoma skin cancer. Adv Exp Med Biol 2017; 996: 27-40.
 
32.
Halpern AC, Kopp LJ. Awareness, knowledge and attitudes to non-melanoma skin cancer and actinic keratosis among the general public. Int J Dermatol 2005; 44: 107-11.
 
33.
Mengqi Chen KL, Zhao H, He X. A systematic review and meta-analysis of the prognostic value of preoperative systemic immunoinflammatory index in patients with non-small cell lung cancer. Chin J Thorac Cardiovasc Surg 2023; 30: 440-6.
 
34.
Holman DM, Ragan KR, Julian AK, Perna FM. The context of sunburn among U.S. adults: common activities and sun protection behaviors. Am J Prev Med 2021; 60: e213-20.
 
35.
Cui N, Zhang H, Chen Z, Yu Z. Prognostic significance of PCT and CRP evaluation for adult ICU patients with sepsis and septic shock: retrospective analysis of 59 cases. J Int Med Res 2019; 47: 1573-9.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top